November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , EVOTEC SE INH O.N. | DE0005664809 , NETRAMARK HOLDINGS INC | CA64119M1059
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
NetraMark Holdings: Next success story – Takeover in 2026?
Artificial intelligence (AI) can save time in drug development and increase the efficiency of clinical trials. In this way, pharmaceutical and biotech companies could save billions in the future and generate revenue more quickly. To this end, NetraMark Holdings has developed the NetraAI platform, specializing in the optimization of clinical trials. NetraAI's capabilities are said to surpass traditional machine learning, generating actionable results even from small and complex clinical data sets.
NetraMark has already secured key customers and established strategic partnerships this year. The next success story came at the beginning of this week. A biopharmaceutical company will use NetraAI for a Phase 3 clinical trial of a novel psychotropic drug. NetraMark's AI will analyze multidimensional clinical data sets and deliver explainable subpopulations. For example, the response to treatment methods and placebos, as well as the occurrence of side effects, will be analyzed. The customer can incorporate the results into its strategy for approval and market access.
With this contract, NetraMark is expanding its portfolio of AI-supported projects in the fields of neuroscience, oncology, and complex pain disorders. Based on its sales success, the Company is a hot AI stock for the coming year. NetraMark's growing revenue and earnings potential, combined with its industry success, position it as a strong candidate for acquisition.
https://youtu.be/Rg_Zn7lctTk?si=u3RaIV0-fB63M2Q-
Evotec: Million-dollar payment evaporates
There has been no takeover speculation for Evotec in recent months. The stock has been highly volatile. In 2025, it has traded as high as nearly EUR 11, but also as low as EUR 5.
Most recently, the biotech company was able to celebrate a million-dollar payment. Partner Bristol Myers Squibb transferred USD 25 million for progress in the joint neurology research project. The funds are intended to accelerate the further development of the joint pipeline for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. The collaboration began in 2016. Since then, several innovative programs have been established, including the EVT8683 project, which has already successfully completed Phase 1 clinical trials.
The partnership was extended by eight years in 2023. The goal is to develop disease-modifying therapies that go beyond simply treating symptoms. Evotec's Chief Scientific Officer, Dr. Cord Dohrmann, emphasized that the payment confirms the close collaboration with Bristol Myers Squibb and underscores the joint mission to create new therapeutic options for patients with neurodegenerative diseases.
Neither the share price nor analysts reacted strongly to the news. Deutsche Bank recently reaffirmed its "Hold" recommendation. Analysts do not expect any positive surprises from today's quarterly figures. Their price target for Evotec shares is EUR 6. The stock is currently trading at just over EUR 7.
BioNTech: Analysts see upside potential
Analysts have recently been much more positive about BioNTech. Following the quarterly figures, Jefferies reaffirmed its "Buy" recommendation. The German biotech leader has generated more revenue than expected. The increase in the annual forecast was also well received. Analysts see the fair value of BioNTech shares at USD 151. The vaccine specialist's shares are currently trading at around USD 103.
BioNTech generated revenue of EUR 1.52 billion in the third quarter of 2025. In the previous year, the figure was EUR 1.24 billion. Despite this growth, the bottom line was a loss of EUR 28.7 million (prior year: profit of EUR 198 million). This is because BioNTech continues to go full throttle in research and development – perhaps NetraMark's AI should be used to save costs. In any case, EUR 565 million was invested. BioNTech can easily afford this. Thanks in part to a payment from Bristol Myers Squibb, cash and cash equivalents stood at EUR 16.7 billion.
Operationally, BioNTech is focusing heavily on its oncology division, particularly on the antibody candidate Pumitamig, which is being tested in several Phase 2 and Phase 3 trials. At the same time, a variant-adapted COVID-19 vaccine for the 2025/26 season was launched in several markets.
BioNTech significantly raised its revenue forecast for 2025 as a whole to EUR 2.6 to 2.8 billion. R&D and administrative costs are expected to be slightly lower than initially anticipated for the year as a whole.
The example of BioNTech shows the sums involved in developing new drugs and how great the need for cost savings is. This opens up exciting growth opportunities for NetraMark and makes the Company a potential takeover candidate in the medium term. Evotec is simply running out of steam at the moment, with even million-dollar payments failing to give the stock any momentum. BioNTech continues to have full coffers and an exciting pipeline.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
